{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:23Z","timestamp":1786982363119,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K08973"],"award-info":[{"award-number":["20K08973"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12282-026-01841-8","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:22:25Z","timestamp":1773404545000},"page":"644-652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Expression of HER2, HER3, and TROP2 in primary tumors and brain metastases of breast cancer"],"prefix":"10.1007","volume":"33","author":[{"given":"S.","family":"Kusuhara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3730-6591","authenticated-orcid":false,"given":"T.","family":"Kogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Funasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Harano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Satomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Suto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mukohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"1841_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10549-017-4107-x","volume":"162","author":"S Matsuo","year":"2017","unstructured":"Matsuo S, Watanabe J, Mitsuya K, Hayashi N, Nakasu Y, Hayashi M. Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up. Breast Cancer Res Treat. 2017;162:169\u201379. https:\/\/doi.org\/10.1007\/s10549-017-4107-x.","journal-title":"Breast Cancer Res Treat"},{"key":"1841_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/neuonc\/now241","volume":"19","author":"R Soffietti","year":"2017","unstructured":"Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017;19:162\u201374. https:\/\/doi.org\/10.1093\/neuonc\/now241.","journal-title":"Neuro Oncol"},{"key":"1841_CR3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/s0002-9440(10)61180-7","volume":"167","author":"RJ Weil","year":"2005","unstructured":"Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol. 2005;167:913\u201320. https:\/\/doi.org\/10.1016\/s0002-9440(10)61180-7.","journal-title":"Am J Pathol"},{"key":"1841_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13036-023-00352-w","volume":"17","author":"MK Farahani","year":"2023","unstructured":"Farahani MK, Gharibshahian M, Rezvani A, Vaez A. Breast cancer brain metastasis: from etiology to state-of-the-art modeling. J Biol Eng. 2023;17:41. https:\/\/doi.org\/10.1186\/s13036-023-00352-w.","journal-title":"J Biol Eng"},{"key":"1841_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2455-9","volume":"35","author":"M Kim","year":"2018","unstructured":"Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, et al. Barriers to effective drug treatment for brain metastases: a multifactorial problem in the delivery of precision medicine. Pharm Res. 2018;35:177. https:\/\/doi.org\/10.1007\/s11095-018-2455-9.","journal-title":"Pharm Res"},{"key":"1841_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327\u201344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8.","journal-title":"Nat Rev Clin Oncol"},{"key":"1841_CR7","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","volume":"28","author":"R Bartsch","year":"2022","unstructured":"Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, et al. Trastuzumab Deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28:1840\u20137. https:\/\/doi.org\/10.1038\/s41591-022-01935-8.","journal-title":"Nat Med"},{"key":"1841_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/neuonc\/noac144","volume":"25","author":"JM P\u00e9rez-Garc\u00eda","year":"2023","unstructured":"P\u00e9rez-Garc\u00eda JM, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol. 2023;25:157\u201366. https:\/\/doi.org\/10.1093\/neuonc\/noac144.","journal-title":"Neuro Oncol"},{"key":"1841_CR9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/1078-0432.Ccr-22-1138","volume":"29","author":"S Kabraji","year":"2023","unstructured":"Kabraji S, Ni J, Sammons S, Li T, Van Swearingen AED, Wang Y, et al. Preclinical and clinical efficacy of Trastuzumab Deruxtecan in breast cancer brain metastases. Clin Cancer Res. 2023;29:174\u201382. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-1138.","journal-title":"Clin Cancer Res"},{"key":"1841_CR10","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.annonc.2024.08.2347","volume":"35","author":"F Andr\u00e9","year":"2024","unstructured":"Andr\u00e9 F, Cort\u00e9s J, Curigliano G, Modi S, Li W, Park YH, et al. A pooled analysis of Trastuzumab Deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases. Ann Oncol. 2024;35:1169\u201380. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2347.","journal-title":"Ann Oncol"},{"key":"1841_CR11","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck N, Ciruelos E, Jerusalem G, M\u00fcller V, Niikura N, Viale G, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat Med. 2024;30:3717\u201327. https:\/\/doi.org\/10.1038\/s41591-024-03261-7.","journal-title":"Nat Med"},{"key":"1841_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"1841_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113328","author":"S Len\u00e1rt","year":"2020","unstructured":"Len\u00e1rt S, Len\u00e1rt P, \u0160marda J, Rem\u0161\u00edk J, Sou\u010dek K, Bene\u0161 P. Trop2: jack of all trades, master of none. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12113328.","journal-title":"Cancers (Basel)"},{"key":"1841_CR14","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1200\/jco.23.00882","volume":"41","author":"IE Krop","year":"2023","unstructured":"Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, et al. Patritumab Deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I\/II trial. J Clin Oncol. 2023;41:5550\u201360. https:\/\/doi.org\/10.1200\/jco.23.00882.","journal-title":"J Clin Oncol"},{"key":"1841_CR15","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.78.8.5147","volume":"78","author":"M Lipinski","year":"1981","unstructured":"Lipinski M, Parks DR, Rouse RV, Herzenberg LA. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci USA. 1981;78:5147\u201350. https:\/\/doi.org\/10.1073\/pnas.78.8.5147.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1841_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s11864-023-01086-z","volume":"24","author":"RK Rader","year":"2023","unstructured":"Rader RK, Anders CK, Lin NU, Sammons SL. Available systemic treatments and emerging therapies for breast cancer brain metastases. Curr Treat Options Oncol. 2023;24:611\u201327. https:\/\/doi.org\/10.1007\/s11864-023-01086-z.","journal-title":"Curr Treat Options Oncol"},{"key":"1841_CR17","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"key":"1841_CR18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/s0140-6736(23)01245-x","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cort\u00e9s J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423\u201333. https:\/\/doi.org\/10.1016\/s0140-6736(23)01245-x.","journal-title":"Lancet"},{"key":"1841_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00635-5","volume":"10","author":"SA Hurvitz","year":"2024","unstructured":"Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, et al. Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2024;10:33. https:\/\/doi.org\/10.1038\/s41523-024-00635-5.","journal-title":"NPJ Breast Cancer"},{"key":"1841_CR20","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/bjc.1998.689","volume":"78","author":"R Naidu","year":"1998","unstructured":"Naidu R, Yadav M, Nair S, Kutty MK. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer. 1998;78:1385\u201390. https:\/\/doi.org\/10.1038\/bjc.1998.689.","journal-title":"Br J Cancer"},{"key":"1841_CR21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/jnci\/djs501","volume":"105","author":"A Ocana","year":"2013","unstructured":"Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: A meta-analysis. J Natl Cancer Inst. 2013;105:266\u201373. https:\/\/doi.org\/10.1093\/jnci\/djs501.","journal-title":"J Natl Cancer Inst"},{"key":"1841_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/bjc.1996.342","volume":"74","author":"A Travis","year":"1996","unstructured":"Travis A, Pinder SE, Robertson JF, Bell JA, Wencyk P, Gullick WJ, et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer. 1996;74:229\u201333. https:\/\/doi.org\/10.1038\/bjc.1996.342.","journal-title":"Br J Cancer"},{"key":"1841_CR23","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/path.1370","volume":"200","author":"CJ Witton","year":"2003","unstructured":"Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200:290\u20137. https:\/\/doi.org\/10.1002\/path.1370.","journal-title":"J Pathol"},{"key":"1841_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.288","author":"B Pistilli","year":"2024","unstructured":"Pistilli B, Pierotti L, Lacroix-Triki M, Vicier C, Frenel JS, D\u2019Hondt V, et al. 340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: a phase II study of Patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+\/HER2- advanced breast cancer (ABC). Ann Oncol. 2024. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.288.","journal-title":"Ann Oncol"},{"key":"1841_CR25","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1200\/jco.23.01476","volume":"41","author":"HA Yu","year":"2023","unstructured":"Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, et al. HERTHENA-Lung01, a phase II trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-mutated non-small-cell lung cancer after Epidermal Growth Factor Receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol. 2023;41:5363\u201375. https:\/\/doi.org\/10.1200\/jco.23.01476.","journal-title":"J Clin Oncol"},{"key":"1841_CR26","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/jco.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020;38:1346\u201366. https:\/\/doi.org\/10.1200\/jco.19.02309.","journal-title":"J Clin Oncol"},{"key":"1841_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2603","volume":"12","author":"L Da Silva","year":"2010","unstructured":"Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A, et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res. 2010;12:R46. https:\/\/doi.org\/10.1186\/bcr2603.","journal-title":"Breast Cancer Res"},{"key":"1841_CR28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-23-0020","author":"E Tomasich","year":"2023","unstructured":"Tomasich E, Steindl A, Paiato C, Hatziioannou T, Kleinberger M, Berchtold L, et al. Frequent overexpression of HER3 in brain metastases from breast and lung cancer. Clin Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-0020.","journal-title":"Clin Cancer Res"},{"key":"1841_CR29","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y, et al. Trastuzumab Deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023;29:2110\u201320. https:\/\/doi.org\/10.1038\/s41591-023-02478-2.","journal-title":"Nat Med"},{"key":"1841_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103209","volume":"9","author":"R Bartsch","year":"2024","unstructured":"Bartsch R, Berghoff AS, Furtner J, Marhold M, Starzer AM, Forstner H, et al. 187P Stage I results of a phase II study of Datopotamab Deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2). ESMO Open. 2024;9:103209. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103209.","journal-title":"ESMO Open"},{"key":"1841_CR31","unstructured":"DATABASE: Phase II Trial of Datopotamab Deruxteckan forBreast Cancer Brain Metastases. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06176261. Accessed 3 Mar 2026."},{"key":"1841_CR32","doi-asserted-by":"publisher","first-page":"TPS2091","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2091","volume":"42","author":"R Bartsch","year":"2024","unstructured":"Bartsch R, Vaz Batista M, Berghoff AS, Furtner J, Marhold M, Oberndorfer F, et al. Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: the TUXEDO-3 phase II trial. J Clin Oncol. 2024;42:TPS2091\u2013TPS2091. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS2091.","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01841-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01841-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01841-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:27:34Z","timestamp":1777382854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01841-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1841"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01841-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7834157\/v1","asserted-by":"object"}]},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takahiro Kogawa received grants from Daiichi Sankyo, Eli Lilly, and AstraZeneca. Toru Mukohara received research funds from Sysmex, Eisai, MSD, Pfizer, AstraZeneca, Ono, Daiichi-Sankyo, and Gilead Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board (IRB) of the National Cancer Center Hospital (IRB number: 2017-502).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}},{"value":"Not Applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}